Overview

Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Status:
Approved for marketing

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Pirfenidone